You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases

Dr. Evan Dellon highlights potential risks with cumulative use of steroids for treatment of various coexisting type 2 inflammatory diseases.

Evan Dellon
MD, MPH
Evan Dellon

Learning objectives

  • Recognize the potential for complications with cumulative exposure to steroid treatment of coexisting diseases with underlying type 2 inflammation

Description

Join global expert Evan Dellon, MD, MPH, as he highlights different ways that corticosteroids may be taken by a patient for various type 2 inflammatory diseases, and discusses the cumulative risk for steroid complications.

Tags
corticosteroidscoexisting diseases
MAT-GLB-2102867 v2.0 07/2021

About this expert

Gastroenterology

Evan Dellon

MD, MPH

Professor of Medicine and Adjunct Professor of Epidemiology | University of North Carolina School of Medicine, Chapel Hill, United States

See author’s profile
Evan Dellon

Related resources

UEGW 2023 | Biologics in EoE
Gastroenterology
expert video

UEGW 2023 | Biologics in EoE

UEGW 2023 | Burden of EoE and Multidimensional Assessment of Disease
Gastroenterology
expert video

UEGW 2023 | Burden of EoE and Multidimensional Assessment of Disease

UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term Disease Control
Gastroenterology
expert video

UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term Disease Control

UEGW 2023 | How Do You and Your Patient Decide What Is Best for Managing Their EoE?
Gastroenterology
expert video

UEGW 2023 | How Do You and Your Patient Decide What Is Best for Managing Their EoE?

UEGW 2023 | How Do You Individualize the Approach to Assessing EoE?
Gastroenterology
expert video

UEGW 2023 | How Do You Individualize the Approach to Assessing EoE?

EAACI 2023 | Recognizing EoE in the Allergy Clinic
Gastroenterology
expert video

EAACI 2023 | Recognizing EoE in the Allergy Clinic

ESPGHAN 2023 | Growing Up With EoE: Patient Care From Adolescence to Adulthood
Gastroenterology
expert video

ESPGHAN 2023 | Growing Up With EoE: Patient Care From Adolescence to Adulthood

ESPGHAN 2023 | Patient Burden and Diagnosis of EoE
Gastroenterology
expert video

ESPGHAN 2023 | Patient Burden and Diagnosis of EoE

ESPGHAN 2023 | Treatment Options for EoE and Importance of Long-term Management
Gastroenterology
expert video

ESPGHAN 2023 | Treatment Options for EoE and Importance of Long-term Management

ESPGHAN 2023 | How Do You Transition EoE Care From Adolescence to Adulthood?
Gastroenterology
expert video

ESPGHAN 2023 | How Do You Transition EoE Care From Adolescence to Adulthood?

Type 2 Inflammation as the Common Thread in Multiple Diseases
Type 2 Inflammation
videoanimation

Type 2 Inflammation as the Common Thread in Multiple Diseases

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients
Type 2 Inflammation
expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Understanding the Pathophysiology of Pediatric Type 2 Inflammatory Diseases

Genetics of Type 2 Inflammation
Type 2 Inflammation
expert video

Genetics of Type 2 Inflammation

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis
Type 2 Inflammation
expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression
Type 2 Inflammation
expert video

AAAAI 2023 | Pediatric Type 2 Inflammatory Disease Progression

AAAAI 2023 | Defining Type 2 Inflammation
Type 2 Inflammation
expert video

AAAAI 2023 | Defining Type 2 Inflammation

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD
Type 2 Inflammation
expert video

AAAAI 2023 | Impact of Barrier Disruption and Type 2 Inflammation in Pediatric Patients With AD

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children
Type 2 Inflammation
expert video

AAAAI 2023 | How Type 2 Inflammation Can Contribute to the Progression of Asthma in Children

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan
Type 2 Inflammation
expert video

AAAAI 2023 | The Role of Type 2 Inflammation in EoE Disease Progression Throughout the Lifespan

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum
Type 2 Inflammation
expert video

Atopic Dermatitis and the Type 2 Inflammatory Disease Spectrum

Type 2 Inflammation in EoE and Impact on Disease Burden
Gastroenterology
expert video

Type 2 Inflammation in EoE and Impact on Disease Burden

Pruritic Dermatoses with a Type 2 Inflammation Component
Type 2 Inflammation
expert video

Pruritic Dermatoses with a Type 2 Inflammation Component

Multidisciplinary Partnership for Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

Type 2 Inflammation Acts on a Range of Skin Barrier Components to Drive Atopic Dermatitis Interview
Type 2 Inflammation
expert video

Type 2 Inflammation Acts on a Range of Skin Barrier Components to Drive Atopic Dermatitis Interview

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis
Type 2 Inflammation
expert video

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis

The Role of IL-4 in Type 2 Inflammation
Type 2 Inflammation
expert video

The Role of IL-4 in Type 2 Inflammation

Overview of EoE Pathophysiology and the Impact on Patient Burden
Gastroenterology
expert video

Overview of EoE Pathophysiology and the Impact on Patient Burden

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE
Gastroenterology
expert video

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

ESPGHAN 2024 | Clinical Management of Young Children With EoE
Gastroenterology
expert video

ESPGHAN 2024 | Clinical Management of Young Children With EoE

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?
Gastroenterology
Podcast

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis
Gastroenterology
Podcast

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

Adaptive Behaviors in EoE Infographic
Gastroenterology
Infographic

Adaptive Behaviors in EoE Infographic

What proportion of patients can achieve control in CRSwNP?
Type 2 Inflammation
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Type 2 Inflammation
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Type 2 Inflammation
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Type 2 Inflammation
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

When is the right time to consider a biologic in patients with CRSwNP?
Type 2 Inflammation
expert video

When is the right time to consider a biologic in patients with CRSwNP?

How often do you suggest to assess sense of smell?
Type 2 Inflammation
expert video

How often do you suggest to assess sense of smell?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Type 2 Inflammation
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

Assessing EoE: Monitoring Patients With EoE in Clinical Practice
Gastroenterology
expert video

Assessing EoE: Monitoring Patients With EoE in Clinical Practice

ADVENT Forum 2022 | Exploring Features in Type 2 Inflammation
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Exploring Features in Type 2 Inflammation

ADVENT Forum 2022 | Delving Into the Latest Pediatric Data for Systemic Agents in AD and Asthma
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Delving Into the Latest Pediatric Data for Systemic Agents in AD and Asthma

ADVENT Forum 2022 | Multidisciplinary Management of Patients with Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Multidisciplinary Management of Patients with Type 2 Inflammatory Diseases

ADVENT Forum 2022 | Therapeutic Mechanisms Targeting Type 2 Pathophysiology
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Therapeutic Mechanisms Targeting Type 2 Pathophysiology

ADVENT Forum 2022 | Type 2 Inflammation Underlies the Pathophysiology of Multiple Diseases
Type 2 Inflammation
expert video

ADVENT Forum 2022 | Type 2 Inflammation Underlies the Pathophysiology of Multiple Diseases

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Trajectories of Type 2 Inflammation in Pediatric Patients
Type 2 Inflammation
expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region